The United States has two viable statutory mechanisms for addressing situations in which patent holders are unable or unwilling to supply sufficient quantities of goods or services to combat the coronavirus crisis: march-in rights under the Bayh-Dole Act and governmental use under 28 U.S.C. § 1498. Though each of these mechanisms presents challenges, these should be surmountable in many cases to ensure that diagnostics, vaccines, therapies and support equipment are produced and distributed rapidly and in sufficient quantities.